Clinical Trials
12
Active:3
Completed:2
Trial Phases
3 Phases
Phase 1:2
Phase 2:1
Phase 3:7
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Phase 3
7 (58.3%)Phase 1
2 (16.7%)1 (8.3%)
Phase 2
1 (8.3%)phase_2_3
1 (8.3%)No trials found
News
FcRn Inhibitors Show Promise in Autoimmune Disease Treatment, Market Set for Growth
FcRn inhibitors are emerging as a targeted therapeutic approach for pathogenic IgG reduction, offering a less invasive alternative to traditional treatments for autoimmune diseases.
Spinal Cord Injury and Ankylosing Spondylitis: Advances in Clinical Trials and Therapies
Spinal Cord Injury (SCI) pipeline includes 35+ therapies from companies like Athersys and NervGen Pharma, targeting mechanisms from stem cell therapy to neuroprotection.